Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Company Overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $15.13 to $15.13
• 50-Day Range: $14.65 to $15.13
• 52-Week Range: $11.53 to $15.89
• Volume: N/A
• Average Volume: 396,929 shs
• Market Capitalization: $223.77 million
• P/E Ratio: 1.09
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MACK Stock Analysis - Frequently Asked Questions

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) issued its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.14.

When did Merrimack Pharmaceuticals' stock split?

Shares of Merrimack Pharmaceuticals reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Merrimack Pharmaceuticals' major shareholders?

Top institutional investors of Merrimack Pharmaceuticals include MassMutual Private Wealth & Trust FSB (0.17%). Insiders that own company stock include Noah G Levy, Eric Andersen, Gary L Crocker, Ana Radeljevic and Ulrik B Nielsen.
View institutional ownership trends.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/10/2019
• Today: 1/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MACK
• Previous Symbol: NASDAQ:MACK
• CUSIP: 59032810
• CIK: 1274792
• Web: www.merrimackpharma.com
• Phone: 617-720-8606
• Fax: 617-491-1386
• Employees: 426
• Year Founded: 2000

Profitability

• EPS (Most Recent Fiscal Year): $13.87
• Trailing P/E Ratio: 1.09
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,180,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1.93%
• Return on Assets: -1.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.78
• Quick Ratio: 10.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 11.55

Miscellaneous

• Outstanding Shares: 14,790,000
• Free Float: 10,267,000
• Market Cap: $223.77 million
• Optionable: Optionable
• Beta: 1.45